NCT02903095View on ClinicalTrials.gov

Single Ascending Dose Study of TD-1439 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

February 28, 2017

Conditions
Healthy Subjects
Interventions
DRUG

TD-1439

DRUG

Placebo

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY

NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects | Biotech Hunter | Biotech Hunter